62 / 74 · 0:53 · Original AXON film
NR / nicotinamide riboside
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
NR | A distinct NAD+ precursor
Nicotinamide riboside, or NR, is another precursor in NAD+ metabolism. It is distinct from NMN and from directly administering NAD+ itself. [1]
HUMAN TRIAL | Crossover design
A randomized crossover trial in healthy middle-aged and older adults compared NR with placebo over two six-week periods. Researchers assessed tolerability and NAD+ metabolism. [1]
Measured: blood-cell NAD+
NR increased NAD+ in blood cells in this study. That is evidence of a biological response, not direct proof of longer life or better memory. [1]
Clinical outcomes require their own evidence
Exploratory cardiovascular findings need further testing. Small, short trials cannot establish broad anti-aging benefits or fully characterize uncommon risks from long-term use. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Martens et al. (2018): Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults →Two six-week periods; peripheral blood mononuclear-cell NAD+ increase; exploratory cardiovascular measures.
